false--12-31Q220200000927066P5Y24637300000.0010.00145000000045000000012584285312603663212584285312198433481922000881330001241880001177950001307320001247570000.0010.001500000050000000068842000396956600042293630000.5040522980
0000927066
2020-01-01
2020-06-30
0000927066
2020-07-29
0000927066
2019-04-01
2019-06-30
0000927066
2020-04-01
2020-06-30
0000927066
2019-01-01
2019-06-30
0000927066
2019-12-31
0000927066
2020-06-30
0000927066
us-gaap:SegmentDiscontinuedOperationsMember
2020-01-01
2020-06-30
0000927066
2019-06-30
0000927066
us-gaap:SegmentContinuingOperationsMember
2020-01-01
2020-06-30
0000927066
2018-12-31
0000927066
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-06-30
0000927066
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2020-04-01
2020-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2020-04-01
2020-06-30
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2020-06-30
0000927066
us-gaap:CommonStockMember
2020-03-31
0000927066
us-gaap:TreasuryStockMember
2020-04-01
2020-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2020-03-31
0000927066
us-gaap:TreasuryStockMember
2020-06-30
0000927066
us-gaap:ParentMember
2020-04-01
2020-06-30
0000927066
us-gaap:TreasuryStockMember
2020-03-31
0000927066
us-gaap:StockAppreciationRightsSARSMember
us-gaap:CommonStockMember
2020-04-01
2020-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:AdditionalPaidInCapitalMember
2020-04-01
2020-06-30
0000927066
us-gaap:NoncontrollingInterestMember
2020-03-31
0000927066
us-gaap:CommonStockMember
2020-06-30
0000927066
us-gaap:ParentMember
2020-06-30
0000927066
us-gaap:StockAppreciationRightsSARSMember
us-gaap:AdditionalPaidInCapitalMember
2020-04-01
2020-06-30
0000927066
us-gaap:NoncontrollingInterestMember
2020-04-01
2020-06-30
0000927066
us-gaap:RetainedEarningsMember
2020-06-30
0000927066
us-gaap:RetainedEarningsMember
2020-04-01
2020-06-30
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2020-03-31
0000927066
us-gaap:StockAppreciationRightsSARSMember
us-gaap:ParentMember
2020-04-01
2020-06-30
0000927066
us-gaap:ParentMember
2020-03-31
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-04-01
2020-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:ParentMember
2020-04-01
2020-06-30
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:CommonStockMember
2020-04-01
2020-06-30
0000927066
us-gaap:RetainedEarningsMember
2020-03-31
0000927066
us-gaap:AdditionalPaidInCapitalMember
2020-06-30
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-03-31
0000927066
us-gaap:NoncontrollingInterestMember
2020-06-30
0000927066
us-gaap:NoncontrollingInterestMember
2019-01-01
2019-06-30
0000927066
us-gaap:NoncontrollingInterestMember
2018-12-31
0000927066
us-gaap:ParentMember
2019-01-01
2019-06-30
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2019-01-01
2019-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2019-01-01
2019-06-30
0000927066
us-gaap:CommonStockMember
2018-12-31
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:ParentMember
2019-01-01
2019-06-30
0000927066
srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember
us-gaap:ParentMember
2018-12-31
0000927066
us-gaap:NoncontrollingInterestMember
2019-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:CommonStockMember
2019-01-01
2019-06-30
0000927066
srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2018-12-31
0000927066
us-gaap:TreasuryStockMember
2019-01-01
2019-06-30
0000927066
us-gaap:ParentMember
2018-12-31
0000927066
us-gaap:ParentMember
2019-06-30
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-06-30
0000927066
us-gaap:RetainedEarningsMember
2019-06-30
0000927066
us-gaap:RetainedEarningsMember
2018-12-31
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:AdditionalPaidInCapitalMember
2019-01-01
2019-06-30
0000927066
us-gaap:RetainedEarningsMember
2019-01-01
2019-06-30
0000927066
us-gaap:TreasuryStockMember
2018-12-31
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2018-12-31
0000927066
us-gaap:CommonStockMember
2019-06-30
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2019-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2018-12-31
0000927066
us-gaap:TreasuryStockMember
2019-06-30
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-12-31
0000927066
srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember
us-gaap:NoncontrollingInterestMember
2018-12-31
0000927066
srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember
us-gaap:RetainedEarningsMember
2018-12-31
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2019-06-30
0000927066
us-gaap:ParentMember
2019-04-01
2019-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2019-03-31
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2019-04-01
2019-06-30
0000927066
us-gaap:TreasuryStockMember
2019-03-31
0000927066
us-gaap:NoncontrollingInterestMember
2019-03-31
0000927066
us-gaap:NoncontrollingInterestMember
2019-04-01
2019-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:CommonStockMember
2019-04-01
2019-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:AdditionalPaidInCapitalMember
2019-04-01
2019-06-30
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2019-03-31
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-04-01
2019-06-30
0000927066
us-gaap:TreasuryStockMember
2019-04-01
2019-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2019-04-01
2019-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:ParentMember
2019-04-01
2019-06-30
0000927066
us-gaap:RetainedEarningsMember
2019-04-01
2019-06-30
0000927066
us-gaap:ParentMember
2019-03-31
0000927066
us-gaap:CommonStockMember
2019-03-31
0000927066
us-gaap:RetainedEarningsMember
2019-03-31
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-03-31
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2020-01-01
2020-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-06-30
0000927066
us-gaap:ParentMember
2020-01-01
2020-06-30
0000927066
us-gaap:TreasuryStockMember
2020-01-01
2020-06-30
0000927066
us-gaap:NoncontrollingInterestMember
2020-01-01
2020-06-30
0000927066
us-gaap:StockAppreciationRightsSARSMember
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-06-30
0000927066
us-gaap:CommonStockMember
2019-12-31
0000927066
us-gaap:NoncontrollingInterestMember
2019-12-31
0000927066
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-06-30
0000927066
us-gaap:RetainedEarningsMember
2019-12-31
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-01-01
2020-06-30
0000927066
dva:TemporaryEquityRedeemableNoncontrollingInterestsMember
2019-12-31
0000927066
us-gaap:StockAppreciationRightsSARSMember
us-gaap:CommonStockMember
2020-01-01
2020-06-30
0000927066
us-gaap:AdditionalPaidInCapitalMember
2019-12-31
0000927066
us-gaap:TreasuryStockMember
2019-12-31
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:ParentMember
2020-01-01
2020-06-30
0000927066
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-12-31
0000927066
us-gaap:ParentMember
2019-12-31
0000927066
us-gaap:RetainedEarningsMember
2020-01-01
2020-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:CommonStockMember
2020-01-01
2020-06-30
0000927066
us-gaap:StockAppreciationRightsSARSMember
us-gaap:ParentMember
2020-01-01
2020-06-30
0000927066
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
dva:CommercialPayorsMember
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
dva:CommercialPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
dva:OtherGovernmentPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
dva:CommercialPayorsMember
2020-04-01
2020-06-30
0000927066
dva:OtherGovernmentPayorsMember
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
dva:OtherSourcesofRevenueMember
2019-04-01
2019-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
2020-04-01
2020-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
2019-04-01
2019-06-30
0000927066
dva:OtherGovernmentPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
us-gaap:IntersegmentEliminationMember
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
dva:OtherSourcesofRevenueMember
2020-04-01
2020-06-30
0000927066
dva:CommercialPayorsMember
2019-04-01
2019-06-30
0000927066
us-gaap:IntersegmentEliminationMember
2020-04-01
2020-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
2020-04-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
us-gaap:IntersegmentEliminationMember
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
dva:CommercialPayorsMember
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
dva:OtherGovernmentPayorsMember
2020-04-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
2019-04-01
2019-06-30
0000927066
dva:OtherSourcesofRevenueMember
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
dva:OtherGovernmentPayorsMember
2019-04-01
2019-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
dva:OtherSourcesofRevenueMember
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
dva:OtherGovernmentPayorsMember
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
dva:OtherSourcesofRevenueMember
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
us-gaap:IntersegmentEliminationMember
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
dva:CommercialPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
us-gaap:IntersegmentEliminationMember
2019-04-01
2019-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
us-gaap:IntersegmentEliminationMember
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
dva:OtherSourcesofRevenueMember
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
2020-01-01
2020-06-30
0000927066
us-gaap:IntersegmentEliminationMember
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
dva:CommercialPayorsMember
2020-01-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
dva:OtherSourcesofRevenueMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
2019-01-01
2019-06-30
0000927066
dva:OtherSourcesofRevenueMember
2019-01-01
2019-06-30
0000927066
dva:OtherGovernmentPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
dva:OtherGovernmentPayorsMember
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
dva:CommercialPayorsMember
2019-01-01
2019-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
dva:OtherSourcesofRevenueMember
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
2019-01-01
2019-06-30
0000927066
dva:CommercialPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
dva:CommercialPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
dva:CommercialPayorsMember
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
us-gaap:IntersegmentEliminationMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
dva:OtherGovernmentPayorsMember
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
dva:OtherGovernmentPayorsMember
2019-01-01
2019-06-30
0000927066
us-gaap:IntersegmentEliminationMember
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
dva:OtherSourcesofRevenueMember
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
dva:CommercialPayorsMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
dva:OtherGovernmentPayorsMember
2020-01-01
2020-06-30
0000927066
us-gaap:IntersegmentEliminationMember
2019-01-01
2019-06-30
0000927066
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
dva:MedicaidandManagedMedicaidMember
2020-01-01
2020-06-30
0000927066
dva:OtherSourcesofRevenueMember
2020-01-01
2020-06-30
0000927066
dva:OtherGovernmentPayorsMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
dva:OtherSourcesofRevenueMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
us-gaap:IntersegmentEliminationMember
2020-01-01
2020-06-30
0000927066
us-gaap:IntersegmentEliminationMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
dva:MedicareandMedicareAdvantageMember
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
dva:MutualFundsAndCommonStockMember
2020-01-01
2020-06-30
0000927066
dva:MutualFundsAndCommonStockMember
2019-01-01
2019-06-30
0000927066
dva:MutualFundsAndCommonStockMember
2019-12-31
0000927066
dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember
2020-06-30
0000927066
us-gaap:ShortTermInvestmentsMember
2020-06-30
0000927066
us-gaap:OtherLongTermInvestmentsMember
2020-06-30
0000927066
dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember
2019-12-31
0000927066
us-gaap:OtherLongTermInvestmentsMember
2019-12-31
0000927066
us-gaap:ShortTermInvestmentsMember
2019-12-31
0000927066
dva:MutualFundsAndCommonStockMember
2020-06-30
0000927066
us-gaap:EquitySecuritiesMember
2019-12-31
0000927066
dva:DeconsolidatedNoncontrollingEntityMember
2019-12-31
0000927066
dva:DeconsolidatedNoncontrollingEntityMember
2020-06-30
0000927066
us-gaap:OtherOwnershipInterestMember
2020-06-30
0000927066
us-gaap:EquitySecuritiesMember
2020-06-30
0000927066
us-gaap:OtherOwnershipInterestMember
2019-12-31
0000927066
dva:ParentCompanyAndRestrictedSubsidiariesMember
srt:MaximumMember
2020-06-30
0000927066
dva:ParentCompanyAndRestrictedSubsidiariesMember
srt:MinimumMember
2020-06-30
0000927066
dva:ParentCompanyAndRestrictedSubsidiariesMember
2020-06-30
0000927066
dva:DeconsolidatedNoncontrollingEntityMember
2020-06-30
0000927066
dva:OtherReportingUnitsMember
2020-01-01
2020-03-31
0000927066
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2020-01-01
2020-06-30
0000927066
country:DE
dva:KidneyCareMember
2019-01-01
2019-03-31
0000927066
2019-01-01
2019-12-31
0000927066
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-12-31
0000927066
us-gaap:AllOtherSegmentsMember
2019-12-31
0000927066
dva:USDialysisAndRelatedLabServicesMember
2020-06-30
0000927066
dva:USDialysisAndRelatedLabServicesMember
2018-12-31
0000927066
us-gaap:AllOtherSegmentsMember
2020-06-30
0000927066
dva:USDialysisAndRelatedLabServicesMember
2019-12-31
0000927066
us-gaap:AllOtherSegmentsMember
2018-12-31
0000927066
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-12-31
0000927066
dva:TermLoanAAndRevolverSubjectToUncappedPortionOfVariabilityOfLIBORMember
us-gaap:LondonInterbankOfferedRateLIBORMember
2020-02-13
2020-02-13
0000927066
dva:TermLoanB1Member
2020-02-13
0000927066
dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember
2020-06-09
2020-06-09
0000927066
dva:TermLoanB1Member
2020-02-13
2020-02-13
0000927066
us-gaap:RevolvingCreditFacilityMember
2020-06-30
0000927066
dva:TermLoanBMember
2020-01-01
2020-06-30
0000927066
dva:A2019InterestRateCapAgreementsEffectiveJune302020Member
2020-01-01
2020-06-30
0000927066
dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember
2020-06-09
0000927066
dva:SeniorNotesFivePointOneTwoFivePercentDueTwentyTwentyFourMember
us-gaap:SubsequentEventMember
2020-07-15
2020-07-15
0000927066
dva:TermLoanAMember
2020-01-01
2020-06-30
0000927066
dva:TermLoanB1Member
us-gaap:LondonInterbankOfferedRateLIBORMember
2020-02-13
2020-02-13
0000927066
dva:TermLoanB1Member
2020-01-01
2020-06-30
0000927066
us-gaap:LetterOfCreditMember
2020-06-30
0000927066
dva:A2015InterestRateCapAgreementsEffectiveJune292018Member
2020-01-01
2020-06-30
0000927066
dva:TermLoanAMember
2020-06-30
0000927066
dva:SeniorSecuredCreditFacilitiesMember
2020-06-30
0000927066
dva:A2019InterestRateCapAgreementsEffectiveJune302020Member
us-gaap:CashFlowHedgingMember
dva:DebtExpenseMember
2020-01-01
2020-06-30
0000927066
srt:MaximumMember
dva:TermLoanFacilityMember
dva:A2019InterestRateCapAgreementsEffectiveJune302020Member
2020-06-30
0000927066
srt:MaximumMember
dva:TermLoanFacilityMember
dva:A2019InterestRateCapAgreementsEffectiveJune302020Member
2020-01-01
2020-06-30
0000927066
dva:A2015InterestRateCapAgreementsEffectiveJune292018Member
us-gaap:CashFlowHedgingMember
dva:DebtExpenseMember
2020-01-01
2020-06-30
0000927066
us-gaap:OtherNoncurrentAssetsMember
dva:A2019InterestRateCapAgreementsEffectiveJune302020Member
2020-06-30
0000927066
srt:MaximumMember
dva:TermLoanFacilityMember
dva:A2015InterestRateCapAgreementsEffectiveJune292018Member
2020-01-01
2020-06-30
0000927066
us-gaap:OtherNoncurrentAssetsMember
dva:A2015InterestRateCapAgreementsEffectiveJune292018Member
2019-12-31
0000927066
us-gaap:OtherNoncurrentAssetsMember
dva:A2019InterestRateCapAgreementsEffectiveJune302020Member
2019-12-31
0000927066
srt:MaximumMember
dva:TermLoanFacilityMember
dva:A2015InterestRateCapAgreementsEffectiveJune292018Member
2020-06-30
0000927066
us-gaap:OtherNoncurrentAssetsMember
dva:A2015InterestRateCapAgreementsEffectiveJune292018Member
2020-06-30
0000927066
dva:TermLoanB1Member
2020-06-30
0000927066
dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember
2020-01-01
2020-06-30
0000927066
dva:FinanceLeaseMember
2020-06-30
0000927066
dva:SeniorNotesFivePointZeroPercentDueTwentyTwentyFiveMember
2020-06-30
0000927066
us-gaap:RevolvingCreditFacilityMember
2020-01-01
2020-06-30
0000927066
dva:SeniorNotesFivePointOneTwoFivePercentDueTwentyTwentyFourMember
2020-01-01
2020-06-30
0000927066
dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember
2019-12-31
0000927066
dva:FinanceLeaseMember
2020-01-01
2020-06-30
0000927066
us-gaap:NotesPayableOtherPayablesMember
2020-01-01
2020-06-30
0000927066
dva:SeniorNotesFivePointZeroPercentDueTwentyTwentyFiveMember
2020-01-01
2020-06-30
0000927066
dva:TermLoanB1Member
2019-12-31
0000927066
dva:TermLoanBMember
2019-12-31
0000927066
dva:CurrentportionoflongtermdebtMember
dva:SeniorNotesFivePointOneTwoFivePercentDueTwentyTwentyFourMember
2020-06-30
0000927066
dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember
2020-06-30
0000927066
us-gaap:NotesPayableOtherPayablesMember
2019-12-31
0000927066
dva:FinanceLeaseMember
2019-12-31
0000927066
us-gaap:NotesPayableOtherPayablesMember
2020-06-30
0000927066
us-gaap:RevolvingCreditFacilityMember
2019-12-31
0000927066
dva:SeniorNotesFivePointZeroPercentDueTwentyTwentyFiveMember
2019-12-31
0000927066
dva:SeniorNotesFivePointOneTwoFivePercentDueTwentyTwentyFourMember
2019-12-31
0000927066
dva:SeniorNotesFivePointOneTwoFivePercentDueTwentyTwentyFourMember
2020-06-30
0000927066
dva:TermLoanBMember
2020-06-30
0000927066
dva:TermLoanAMember
2019-12-31
0000927066
us-gaap:InterestRateCapMember
us-gaap:CashFlowHedgingMember
dva:DebtExpenseMember
2020-04-01
2020-06-30
0000927066
us-gaap:CashFlowHedgingMember
dva:IncomeTaxExpenseBenefitMember
2020-01-01
2020-06-30
0000927066
us-gaap:CashFlowHedgingMember
dva:IncomeTaxExpenseBenefitMember
2019-04-01
2019-06-30
0000927066
us-gaap:CashFlowHedgingMember
2019-01-01
2019-06-30
0000927066
us-gaap:CashFlowHedgingMember
dva:IncomeTaxExpenseBenefitMember
2019-01-01
2019-06-30
0000927066
us-gaap:CashFlowHedgingMember
2020-04-01
2020-06-30
0000927066
us-gaap:InterestRateCapMember
us-gaap:CashFlowHedgingMember
dva:DebtExpenseMember
2020-01-01
2020-06-30
0000927066
us-gaap:CashFlowHedgingMember
2019-04-01
2019-06-30
0000927066
us-gaap:CashFlowHedgingMember
dva:IncomeTaxExpenseBenefitMember
2020-04-01
2020-06-30
0000927066
us-gaap:InterestRateCapMember
us-gaap:CashFlowHedgingMember
dva:DebtExpenseMember
2019-04-01
2019-06-30
0000927066
us-gaap:InterestRateCapMember
us-gaap:CashFlowHedgingMember
dva:DebtExpenseMember
2019-01-01
2019-06-30
0000927066
us-gaap:CashFlowHedgingMember
2020-01-01
2020-06-30
0000927066
dva:USAttorneyPrescriptionDrugInvestigationMember
2017-12-01
2017-12-31
0000927066
dva:USAttorneyPrescriptionDrugInvestigationMember
dva:IncrementalCashPortionMember
2017-12-01
2017-12-31
0000927066
dva:StockholderDerivativeLitigationMember
2017-08-15
2017-08-15
0000927066
dva:USAttorneyPrescriptionDrugInvestigationMember
dva:CashPaidForPortionPreviouslyRefundedMember
2017-12-01
2017-12-31
0000927066
dva:CommitmentsToProvideOperatingCapitalMember
2020-06-30
0000927066
dva:The2011IncentiveAwardPlanMember
2020-04-01
2020-06-30
0000927066
us-gaap:StockAppreciationRightsSARSMember
2020-01-01
2020-06-30
0000927066
us-gaap:RestrictedStockUnitsRSUMember
2020-01-01
2020-06-30
0000927066
us-gaap:GeneralAndAdministrativeExpenseMember
2020-01-01
2020-06-30
0000927066
dva:PremiumPricedStockSettledStockAppreciationRightsMember
2020-01-23
2020-01-23
0000927066
dva:PremiumPricedStockSettledStockAppreciationRightsMember
2020-01-23
0000927066
dva:The2020IncentiveAwardPlanMember
2020-06-11
0000927066
srt:MaximumMember
dva:The2020IncentiveAwardPlanMember
2020-04-01
2020-06-30
0000927066
dva:PremiumPricedStockSettledStockAppreciationRightsMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember
2020-01-23
2020-01-23
0000927066
dva:PremiumPricedStockSettledStockAppreciationRightsMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember
2020-01-23
2020-01-23
0000927066
us-gaap:GeneralAndAdministrativeExpenseMember
2019-01-01
2019-06-30
0000927066
dva:PremiumPricedStockSettledStockAppreciationRightsMember
2019-11-04
2019-11-04
0000927066
dva:The2011IncentiveAwardPlanMember
2020-06-11
0000927066
dva:OpenMarketPurchasesMember
2020-04-01
2020-06-30
0000927066
dva:OpenMarketPurchasesMember
2020-01-01
2020-06-30
0000927066
dva:OpenMarketPurchasesMember
2019-04-01
2019-06-30
0000927066
dva:OpenMarketPurchasesMember
2019-01-01
2019-06-30
0000927066
us-gaap:SubsequentEventMember
2020-07-29
0000927066
2019-11-04
0000927066
us-gaap:SubsequentEventMember
2020-07-01
2020-07-29
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-04-01
2019-06-30
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-06-30
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-06-30
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2018-12-31
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-03-31
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-06-30
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-03-31
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2018-12-31
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-06-30
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2018-12-31
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-03-31
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-12-31
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2020-03-31
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2020-04-01
2020-06-30
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-06-30
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2020-06-30
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-06-30
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2020-04-01
2020-06-30
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2020-06-30
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2020-04-01
2020-06-30
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-06-30
0000927066
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2020-03-31
0000927066
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-12-31
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2020-06-30
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-12-31
0000927066
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2020-03-31
0000927066
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2020-06-30
0000927066
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
dva:ForeignDialysisCentersMember
2020-01-01
2020-06-30
0000927066
srt:MaximumMember
dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember
dva:OtherCompaniesMember
2020-01-01
2020-06-30
0000927066
dva:RMSLifelineMember
2020-05-01
2020-05-01
0000927066
srt:MinimumMember
dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember
dva:OtherCompaniesMember
2020-01-01
2020-06-30
0000927066
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
dva:OtherAccruedLiabilitiesMember
2020-06-30
0000927066
us-gaap:OtherNoncurrentLiabilitiesMember
2020-06-30
0000927066
dva:OtherCompaniesMember
2020-06-30
0000927066
us-gaap:NoncompeteAgreementsMember
2020-01-01
2020-06-30
0000927066
srt:MaximumMember
2020-01-01
2020-06-30
0000927066
2020-03-31
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
2017-12-05
2017-12-05
0000927066
2019-06-19
2019-06-19
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
dva:CoronavirusAidReliefAndEconomicSecurityActAdditionalTaxBenefitMember
2020-01-01
2020-06-30
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
2019-06-19
2019-06-19
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
2019-01-01
2019-12-31
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
2019-04-01
2019-06-30
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
2020-04-01
2020-06-30
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
2020-01-01
2020-06-30
0000927066
us-gaap:DiscontinuedOperationsHeldforsaleMember
dva:DaVitaMedicalGroupMember
2019-01-01
2019-06-30
0000927066
us-gaap:VariableInterestEntityPrimaryBeneficiaryMember
2020-06-30
0000927066
us-gaap:InterestRateCapMember
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:InterestRateCapMember
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:InterestRateCapMember
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:InterestRateCapMember
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
2020-01-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
2019-01-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
2020-01-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
2019-01-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
2019-04-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
dva:ExternalSourcesMember
2019-04-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
2020-04-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
us-gaap:IntersubsegmentEliminationsMember
2020-01-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
2019-04-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
2020-01-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
dva:ExternalSourcesMember
2020-04-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
dva:ExternalSourcesMember
2019-01-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
dva:ExternalSourcesMember
2020-01-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
us-gaap:IntersubsegmentEliminationsMember
2019-04-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
2020-04-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
us-gaap:IntersubsegmentEliminationsMember
2019-04-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
us-gaap:IntersubsegmentEliminationsMember
2019-01-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
2019-01-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
us-gaap:IntersubsegmentEliminationsMember
2020-04-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
dva:USDialysisAndRelatedLabServicesMember
us-gaap:IntersubsegmentEliminationsMember
2020-04-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
2019-04-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
us-gaap:IntersubsegmentEliminationsMember
2020-01-01
2020-06-30
0000927066
us-gaap:OperatingSegmentsMember
us-gaap:AllOtherSegmentsMember
us-gaap:IntersubsegmentEliminationsMember
2019-01-01
2019-06-30
0000927066
us-gaap:OperatingSegmentsMember
2020-04-01
2020-06-30
0000927066
dva:DaVitaMedicalGroupMember
2019-01-01
2019-06-30
0000927066
dva:DaVitaMedicalGroupMember
2020-01-01
2020-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2020-01-01
2020-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2020-01-01
2020-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2020-01-01
2020-06-30
0000927066
srt:ConsolidationEliminationsMember
2020-01-01
2020-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-01-01
2019-06-30
0000927066
srt:ConsolidationEliminationsMember
2019-01-01
2019-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-01-01
2019-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2019-01-01
2019-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-06-30
0000927066
srt:ConsolidationEliminationsMember
2018-12-31
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-12-31
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2018-12-31
0000927066
srt:ConsolidationEliminationsMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2019-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2018-12-31
0000927066
srt:ConsolidationEliminationsMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000927066
srt:ConsolidationEliminationsMember
2019-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2020-06-30
0000927066
srt:ConsolidationEliminationsMember
2020-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2020-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2020-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2019-04-01
2019-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-04-01
2019-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-04-01
2019-06-30
0000927066
srt:ConsolidationEliminationsMember
2019-04-01
2019-06-30
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-12-31
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2019-12-31
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2019-12-31
0000927066
srt:ConsolidationEliminationsMember
2019-12-31
0000927066
srt:NonGuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2020-04-01
2020-06-30
0000927066
srt:ConsolidationEliminationsMember
2020-04-01
2020-06-30
0000927066
srt:ParentCompanyMember
srt:ReportableLegalEntitiesMember
2020-04-01
2020-06-30
0000927066
srt:GuarantorSubsidiariesMember
srt:ReportableLegalEntitiesMember
2020-04-01
2020-06-30
0000927066
dva:NewCreditAgreementMember
2019-08-12
iso4217:USD
xbrli:shares
xbrli:pure
dva:segment
iso4217:USD
xbrli:shares
dva:clinic
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
| |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended June 30, 2020
or
|
| |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___________ to ___________
Commission File Number: 1-14106
DAVITA INC.
|
| | |
Delaware | | 51-0354549 |
(State of incorporation) | | (I.R.S. Employer Identification No.) |
|
| | |
2000 16th Street |
Denver, | CO | 80202 |
Telephone number (720) 631-2100
Securities registered pursuant to Section 12(b) of the Act:
|
| | | | |
Title of each class: | | Trading symbol(s): | | Name of each exchange on which registered: |
Common Stock, $0.001 par value | | DVA | | NYSE |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
| | | |
Large accelerated filer | ☒ | Accelerated filer | ☐ |
| | | |
Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | |
Emerging growth company | ☐ | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒
As of July 29, 2020, the number of shares of the Registrant’s common stock outstanding was approximately 122.0 million shares.
DAVITA INC.
INDEX
|
| | | | |
| | | | Page No. |
| | PART I. FINANCIAL INFORMATION | | |
| | | | |
Item 1. | | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
Item 2. | | | | |
Item 3. | | | | |
Item 4. | | | | |
| | | | |
| | PART II. OTHER INFORMATION | | |
Item 1. | | | | |
Item 1A. | | | | |
Item 2. | | | | |
Item 6. | | | | |
| | | | |
Note: Items 3, 4 and 5 of Part II are omitted because they are not applicable.
DAVITA INC.
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(dollars in thousands, except per share data)
|
| | | | | | | | | | | | | | | |
| Three months ended June 30, | | Six months ended June 30, |
| 2020 | | 2019 | | 2020 | | 2019 |
Dialysis patient service revenues | $ | 2,758,197 |
| | $ | 2,723,816 |
| | $ | 5,471,478 |
| | $ | 5,353,505 |
|
Other revenues | 121,782 |
| | 118,889 |
| | 249,738 |
| | 232,312 |
|
Total revenues | 2,879,979 |
| | 2,842,705 |
| | 5,721,216 |
| | 5,585,817 |
|
Operating expenses and charges: | |
| | |
| | |
| | |
|
Patient care costs | 1,984,564 |
| | 1,957,753 |
| | 3,960,013 |
| | 3,922,688 |
|
General and administrative | 316,209 |
| | 275,338 |
| | 579,785 |
| | 526,151 |
|
Depreciation and amortization | 157,376 |
| | 152,242 |
| | 312,055 |
| | 300,770 |
|
Equity investment income | (4,342 | ) | | (4,514 | ) | | (22,185 | ) | | (7,222 | ) |
Loss on changes in ownership interest, net | 16,252 |
| | — |
| | 16,252 |
| | — |
|
Goodwill impairment charges | — |
| | — |
| | — |
| | 41,037 |
|
Total operating expenses and charges | 2,470,059 |
| | 2,380,819 |
| | 4,845,920 |
| | 4,783,424 |
|
Operating income | 409,920 |
| | 461,886 |
| | 875,296 |
| | 802,393 |
|
Debt expense | (81,381 | ) | | (131,666 | ) | | (169,984 | ) | | (263,185 | ) |
Debt prepayment and refinancing charges | — |
| | (12,160 | ) | | (2,948 | ) | | (12,160 | ) |
Other income, net | 9,545 |
| | 5,643 |
| | 5,195 |
| | 12,583 |
|
Income from continuing operations before income taxes | 338,084 |
| | 323,703 |
| | 707,559 |
| | 539,631 |
|
Income tax expense | 83,212 |
| | 75,938 |
| | 174,772 |
| | 132,684 |
|
Net income from continuing operations | 254,872 |
| | 247,765 |
| | 532,787 |
| | 406,947 |
|
Net income from discontinued operations, net of tax | — |
| | 79,392 |
| | 9,980 |
| | 109,697 |
|
Net income | 254,872 |
| | 327,157 |
| | 542,767 |
| | 516,644 |
|
Less: Net income attributable to noncontrolling interests | (53,270 | ) | | (53,606 | ) | | (101,572 | ) | | (93,804 | ) |
Net income attributable to DaVita Inc. | $ | 201,602 |
| | $ | 273,551 |
| | $ | 441,195 |
| | $ | 422,840 |
|
| | | | | | | |
Earnings per share attributable to DaVita Inc.: | |
| | |
| | |
| | |
|
Basic net income from continuing operations per share | $ | 1.65 |
| | $ | 1.17 |
| | $ | 3.49 |
| | $ | 1.89 |
|
Basic net income per share | $ | 1.65 |
| | $ | 1.64 |
| | $ | 3.57 |
| | $ | 2.54 |
|
Diluted net income from continuing operations per share | $ | 1.62 |
| | $ | 1.16 |
| | $ | 3.44 |
| | $ | 1.89 |
|
Diluted net income per share | $ | 1.62 |
| | $ | 1.64 |
| | $ | 3.52 |
| | $ | 2.54 |
|
| | | | | | | |
Weighted average shares for earnings per share: | | | | | |
| | |
|
Basic | 122,074,452 |
| | 166,346,041 |
| | 123,485,412 |
| | 166,366,886 |
|
Diluted | 124,068,278 |
| | 166,799,525 |
| | 125,478,913 |
| | 166,789,978 |
|
| | | | | | | |
Amounts attributable to DaVita Inc.: | | | | | | | |
Net income from continuing operations | $ | 201,602 |
| | $ | 194,223 |
| | $ | 431,215 |
| | $ | 314,477 |
|
Net income from discontinued operations | — |
| | 79,328 |
| | 9,980 |
| | 108,363 |
|
Net income attributable to DaVita Inc. | $ | 201,602 |
| | $ | 273,551 |
| | $ | 441,195 |
| | $ | 422,840 |
|
See notes to condensed consolidated financial statements.
DAVITA INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
(dollars in thousands)
|
| | | | | | | | | | | | | | | |
| Three months ended June 30, | | Six months ended June 30, |
| 2020 | | 2019 | | 2020 | | 2019 |
Net income | $ | 254,872 |
| | $ | 327,157 |
| | $ | 542,767 |
| | $ | 516,644 |
|
Other comprehensive income, net of tax: | |
| | |
| | |
| | |
|
Unrealized losses on interest rate cap agreements: | |
| | |
| | |
| | |
|
Unrealized losses | (1,824 | ) | | (31 | ) | | (14,842 | ) | | (611 | ) |
Reclassifications of net realized losses into net income | 1,623 |
| | 1,606 |
| | 3,246 |
| | 3,212 |
|
Unrealized gains (losses) on foreign currency translation: | | | |
| | | | |
|
Foreign currency translation adjustments | 5,619 |
| | 12,365 |
| | (76,013 | ) | | (1,288 | ) |
Other comprehensive income (loss) | 5,418 |
| | 13,940 |
| | (87,609 | ) | | 1,313 |
|
Total comprehensive income | 260,290 |
| | 341,097 |
| | 455,158 |
| | 517,957 |
|
Less: Comprehensive income attributable to noncontrolling interests | (53,270 | ) | | (53,606 | ) | | (101,572 | ) | | (93,804 | ) |
Comprehensive income attributable to DaVita Inc. | $ | 207,020 |
| | $ | 287,491 |
| | $ | 353,586 |
| | $ | 424,153 |
|
See notes to condensed consolidated financial statements.
DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(dollars in thousands, except per share data)
|
| | | | | | | |
| June 30, 2020 | | December 31, 2019 |
ASSETS | |
| | |
|
Cash and cash equivalents | $ | 2,928,910 |
| | $ | 1,102,372 |
|
Restricted cash and equivalents | 106,809 |
| | 106,346 |
|
Short-term investments | 154,115 |
| | 11,572 |
|
Accounts receivable | 1,772,259 |
| | 1,795,598 |
|
Inventories | 97,902 |
| | 97,949 |
|
Other receivables | 614,606 |
| | 489,695 |
|
Prepaid and other current assets | 63,266 |
| | 66,866 |
|
Income tax receivable | 41,963 |
| | 19,772 |
|
Total current assets | 5,779,830 |
| | 3,690,170 |
|
Property and equipment, net of accumulated depreciation of $4,229,363 and $3,969,566, respectively | 3,417,918 |
| | 3,473,384 |
|
Operating lease right-of-use assets | 2,826,620 |
| | 2,830,047 |
|
Intangible assets, net of accumulated amortization of $88,133 and $81,922, respectively | 113,379 |
| | 135,684 |
|
Equity method and other investments | 255,489 |
| | 241,983 |
|
Long-term investments | 28,340 |
| | 36,519 |
|
Other long-term assets | 92,909 |
| | 115,972 |
|
Goodwill | 6,790,606 |
| | 6,787,635 |
|
| $ | 19,305,091 |
| | $ | 17,311,394 |
|
LIABILITIES AND EQUITY | |
| | |
|
Accounts payable | $ | 357,283 |
| | $ | 403,840 |
|
Other liabilities | 902,019 |
| | 756,174 |
|
Accrued compensation and benefits | 686,700 |
| | 695,052 |
|
Current portion of operating lease liabilities | 360,405 |
| | 343,912 |
|
Current portion of long-term debt | 1,906,560 |
| | 130,708 |
|
Income tax payable | 61,596 |
| | 42,412 |
|
Total current liabilities | 4,274,563 |
| | 2,372,098 |
|
Long-term operating lease liabilities | 2,709,569 |
| | 2,723,800 |
|
Long-term debt | 7,894,674 |
| | 7,977,526 |
|
Other long-term liabilities | 144,121 |
| | 160,809 |
|
Deferred income taxes | 706,410 |
| | 577,543 |
|
Total liabilities | 15,729,337 |
| | 13,811,776 |
|
Commitments and contingencies | | | |
Noncontrolling interests subject to put provisions | 1,241,937 |
| | 1,180,376 |
|
Equity: | |
| | |
|
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued) | — |
| | — |
|
Common stock ($0.001 par value, 450,000,000 shares authorized; 126,036,632 and 121,984,334 shares issued and outstanding at June 30, 2020, respectively and 125,842,853 shares issued and outstanding at December 31, 2019) | 126 |
| | 126 |
|
Additional paid-in capital | 719,102 |
| | 749,043 |
|
Retained earnings | 1,872,933 |
| | 1,431,738 |
|
Treasury stock (4,052,298 and zero shares, respectively) | (303,139 | ) | | — |
|
Accumulated other comprehensive loss | (135,107 | ) | | (47,498 | ) |
Total DaVita Inc. shareholders' equity | 2,153,915 |
| | 2,133,409 |
|
Noncontrolling interests not subject to put provisions | 179,902 |
| | 185,833 |
|
Total equity | 2,333,817 |
| | 2,319,242 |
|
| $ | 19,305,091 |
| | $ | 17,311,394 |
|
See notes to condensed consolidated financial statements.
DAVITA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(dollars in thousands) |
| | | | | | | |
| Six months ended June 30, |
| 2020 | | 2019 |
Cash flows from operating activities: | |
| | |
|
Net income | $ | 542,767 |
| | $ | 516,644 |
|
Adjustments to reconcile net income to net cash provided by operating activities: | | | |
|
Depreciation and amortization | 312,055 |
| | 300,770 |
|
Debt refinancing charges | 884 |
| | — |
|
Impairment charges | — |
| | 41,037 |
|
Stock-based compensation expense | 42,125 |
| | 29,045 |
|
Deferred income taxes | 132,101 |
| | 60,706 |
|
Equity investment (loss) income, net | (6,494 | ) | | 2,631 |
|
Loss on sales of business interests, net | 16,252 |
| | 23,022 |
|
Other non-cash charges, net | (5,885 | ) | | 25,857 |
|
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures: | | | |
Accounts receivable | 15,194 |
| | (288,437 | ) |
Inventories | (696 | ) | | 11,542 |
|
Other receivables and other current assets | (131,988 | ) | | (5,142 | ) |
Other long-term assets | 1,950 |
| | (410 | ) |
Accounts payable | (15,858 | ) | | (68,887 | ) |
Accrued compensation and benefits | (19,325 | ) | | (88,473 | ) |
Other current liabilities | 146,490 |
| | 151,780 |
|
Income taxes | (4,800 | ) | | 57,551 |
|
Other long-term liabilities | (13,269 | ) | | (18,121 | ) |
Net cash provided by operating activities | 1,011,503 |
| | 751,115 |
|
Cash flows from investing activities: | | | |
|
Additions of property and equipment | (291,667 | ) | | (373,918 | ) |
Acquisitions | (44,267 | ) | | (65,970 | ) |
Proceeds from asset and business sales | 70,615 |
| | 3,851,381 |
|
Purchase of debt investments held-to-maturity | (142,483 | ) | | (3,322 | ) |
Purchase of other debt and equity investments | (3,034 | ) | | (4,812 | ) |
Proceeds from debt investments held-to-maturity | 7,621 |
| | — |
|
Proceeds from sale of other debt and equity investments | 3,438 |
| | 5,893 |
|
Purchase of equity method investments | (8,101 | ) | | (6,715 | ) |
Distributions from equity method investments | 739 |
| | 155 |
|
Net cash (used in) provided by investing activities | (407,139 | ) | | 3,402,692 |
|
Cash flows from financing activities: | | | |
Borrowings | 2,324,300 |
| | 32,367,300 |
|
Payments on long-term debt | (635,695 | ) | | (33,527,788 | ) |
Deferred financing and debt redemption costs | (20,375 | ) | | (3,621 | ) |
Purchase of treasury stock | (321,798 | ) | | (73,078 | ) |
Distributions to noncontrolling interests | (118,553 | ) | | (95,714 | ) |
Stock award exercises and other share issuances, net | (2,106 | ) | | 2,107 |
|
Contributions from noncontrolling interests | 20,582 |
| | 31,281 |
|
Purchases of noncontrolling interests | (6,782 | ) | | (11,040 | ) |
Net cash provided by (used in) financing activities | 1,239,573 |
| | (1,310,553 | ) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (16,936 | ) | | (77 | ) |
Net increase in cash, cash equivalents and restricted cash | 1,827,001 |
| | 2,843,177 |
|
Less: Net decrease in cash, cash equivalents and restricted cash from discontinued operations | — |
| | (423,813 | ) |
Net increase in cash, cash equivalents and restricted cash from continuing operations | 1,827,001 |
| | 3,266,990 |
|
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year | 1,208,718 |
| | 415,420 |
|
Cash, cash equivalents and restricted cash of continuing operations at end of the year | $ | 3,035,719 |
| | $ | 3,682,410 |
|
See notes to condensed consolidated financial statements.
DAVITA INC.
CONSOLIDATED STATEMENTS OF EQUITY
(unaudited)
(dollars and shares in thousands)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, 2020 |
| Non- controlling interests subject to put provisions | | DaVita Inc. Shareholders’ Equity | | Non- controlling interests not subject to put provisions |
| | |
| | Common stock | | Additional paid-in capital | | Retained earnings | | Treasury stock | | Accumulated other comprehensive loss | | | |
| | Shares | | Amount | | | | Shares | | Amount | | | Total | |
Balance at March 31, 2020 | $ | 1,228,036 |
| | 125,857 |
| | $ | 126 |
| | $ | 720,053 |
| | $ | 1,671,331 |
| | (4,052 | ) | | $ | (303,139 | ) | | $ | (140,525 | ) | | $ | 1,947,846 |
| | $ | 185,498 |
|
Comprehensive income: | | | | | | | | | | | | | | | | | | | |
Net income | 34,707 |
| | | | | | | | 201,602 |
| | | | | | | | 201,602 |
| | 18,563 |
|
Other comprehensive loss | | | | | | | | | | | | | | | 5,418 |
| | 5,418 |
| | |
Stock unit shares issued | | | 153 |
| | | | (7,076 | ) | | | | | | | | | | (7,076 | ) | | |
Stock appreciation rights shares issued | | | 27 |
| | | | (815 | ) | | | | | | | | | | (815 | ) | | |
Stock-settled stock-based compensation expense | | | | | | | 21,881 |
| | | | | | | | | | 21,881 |
| | |
Changes in noncontrolling interest from: | | | | | | | | | | | | | | | | | | | |
Distributions | (39,569 | ) | | | | | | | | | | | | | | | | | | (20,853 | ) |
Contributions | 8,812 |
| | | | | | | | | | | | | | | | | | 2,383 |
|
Acquisitions and divestitures | (3,214 | ) | | | | | | | | | | | | | | | | | | (1,383 | ) |
Partial purchases | (6,418 | ) | | | | | | 4,642 |
| | | | | | | | | | 4,642 |
| | (4,306 | ) |
Fair value remeasurements | 19,583 |
| | | | | | (19,583 | ) | | | | | | | | | | (19,583 | ) | | |
Purchase of treasury stock | | | | | | | | | | |
|
| |
|
| | | |
|
| | |
Balance at June 30, 2020 | $ | 1,241,937 |
| | 126,037 |
| | $ | 126 |
| | $ | 719,102 |
| | $ | 1,872,933 |
| | (4,052 | ) | | $ | (303,139 | ) | | $ | (135,107 | ) | | $ | 2,153,915 |
| | $ | 179,902 |
|
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Six months ended June 30, 2020 |
| Non- controlling interests subject to put provisions | | DaVita Inc. Shareholders’ Equity | | Non- controlling interests not subject to put provisions |
| | |
| | Common stock | | Additional paid-in capital | | Retained earnings | | Treasury stock | | Accumulated other comprehensive loss | | | |
| | Shares | | Amount | | | | Shares | | Amount | | | Total | |
Balance at December 31, 2019 | $ | 1,180,376 |
| | 125,843 |
| | $ | 126 |
| | $ | 749,043 |
| | $ | 1,431,738 |
| | — |
| | $ | — |
| | $ | (47,498 | ) | | $ | 2,133,409 |
| | $ | 185,833 |
|
Comprehensive income: | | | | | | | | | | | | | | | | | | | |
Net income | 66,883 |
| | | | | | | | 441,195 |
| | | | | | | | 441,195 |
| | 34,689 |
|
Other comprehensive loss | | | | | | | | | | | | | | | (87,609 | ) | | (87,609 | ) | | |
Stock unit shares issued | | | 161 |
| | | | (7,151 | ) | | | | | | | | | | (7,151 | ) | | |
Stock appreciation rights shares issued | | | 33 |
| | | | (1,060 | ) | | | | | | | | | | (1,060 | ) | | |
Stock-settled stock-based compensation expense | | | | | | | 41,678 |
| | | | | | | | | | 41,678 |
| | |
Changes in noncontrolling interest from: | | | | | | | | | | | | | | | | | | | |
Distributions | (77,135 | ) | | | | | | | | | | | | | | | | | | (41,418 | ) |
Contributions | 14,095 |
| | | | | | | | | | | | | | | | | | 6,487 |
|
Acquisitions and divestitures | (3,214 | ) | | | | | | | | | | | | | | | | | | (1,383 | ) |
Partial purchases | (6,673 | ) | | | | | | 4,197 |
| | | | | | | | | | 4,197 |
| | (4,306 | ) |
Fair value remeasurements | 67,605 |
| | | | | | (67,605 | ) | | | | | | | | | | (67,605 | ) | | |
Purchase of treasury stock | | | | | | | | | | | (4,052 | ) | | (303,139 | ) | | | | (303,139 | ) | | |
Balance at June 30, 2020 | $ | 1,241,937 |
| | 126,037 |
| | $ | 126 |
| | $ | 719,102 |
| | $ | 1,872,933 |
| | (4,052 | ) | | $ | (303,139 | ) | | $ | (135,107 | ) | | $ | 2,153,915 |
| | $ | 179,902 |
|
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, 2019 |
| Non- controlling interests subject to put provisions | | DaVita Inc. Shareholders’ Equity | | Non- controlling interests not subject to put provisions |
| | |
| | Common stock | | Additional paid-in capital | | Retained earnings | | Treasury stock | | Accumulated other comprehensive loss | | | |
| | Shares | | Amount | | | | Shares | | Amount | | | Total | |
Balance at March 31, 2019 | $ | 1,143,044 |
| | 166,396 |
| | $ | 166 |
| | $ | 990,380 |
| | $ | 2,932,359 |
| | — |
| | $ | — |
| | $ | (47,551 | ) | | $ | 3,875,354 |
| | $ | 211,319 |
|
Comprehensive income: | | | | | | | | | | | | | | | | | | | |
Net income | 37,911 |
| | | | | | | | 273,551 |
| | | | | | | | 273,551 |
| | 15,695 |
|
Other comprehensive loss | | | | | | | | | | | | | | | 13,940 |
| | 13,940 |
| | |
Stock unit shares issued | | | 137 |
| | 1 |
| | (3,142 | ) | | | | | | | | | | (3,141 | ) | | |
Stock-settled stock-based compensation expense | | | | | | | 16,908 |
| | | | | | | | | | 16,908 |
| | |
Changes in noncontrolling interest from: | | | | | | | | | | | | | | | | | | | |
Distributions | (32,670 | ) | | | | | | | | | | | | | | | | | | (18,814 | ) |
Contributions | 9,353 |
| | | | | | | | | | | | | | | | | | 2,981 |
|
Acquisitions and divestitures | 111 |
| | | | | |
|
| | | | | | | | | | — |
| | (1,991 | ) |
Partial purchases | (281 | ) | |